{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:51:49Z","timestamp":1792792309889,"version":"4.5.0"},"reference-count":58,"publisher":"Elsevier BV","issue":"50","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,12,15]],"date-time":"2016-12-15T00:00:00Z","timestamp":1481760000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Novartis\/GSK"},{"DOI":"10.13039\/100000865","name":"Bill & Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1134011"],"award-info":[{"award-number":["OPP1134011"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.vaccine.2016.12.029","type":"journal-article","created":{"date-parts":[[2016,12,22]],"date-time":"2016-12-22T20:46:46Z","timestamp":1482439606000},"page":"7307-7314","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":78,"title":["WHO consultation on group B Streptococcus vaccine development: Report from a meeting held on 27\u201328 April 2016"],"prefix":"10.1016","volume":"37","author":[{"given":"Miwako","family":"Kobayashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie J.","family":"Schrag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Alderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shabir A.","family":"Madhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol J.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajoke","family":"Sobanjo-ter Meulen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Kaslow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter G.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasee S.","family":"Moorthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Vekemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2016.12.029_b0005","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1016\/j.vaccine.2016.02.078","article-title":"Report from the World Health Organization's Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 7\u20139th Sep 2015","volume":"34","author":"Giersing","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.12.029_b0010","doi-asserted-by":"crossref","first-page":"638","DOI":"10.3201\/eid2104.141562","article-title":"Increased risk for group B Streptococcus sepsis in young infants exposed to HIV, Soweto, South Africa, 2004\u20132008(1)","volume":"21","author":"Cutland","year":"2015","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2016.12.029_b0015","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1128\/CMR.11.3.497","article-title":"Epidemiology of group B streptococcal disease in the United States: shifting paradigms","volume":"11","author":"Schuchat","year":"1998","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.vaccine.2016.12.029_b0020","series-title":"Remington and Klein's infectious diseases of the fetus and newborn infant","first-page":"411","article-title":"Group B streptococcal infections","author":"Edwards","year":"2016"},{"key":"10.1016\/j.vaccine.2016.12.029_b0025","doi-asserted-by":"crossref","first-page":"e631","DOI":"10.1542\/peds.2010-0183","article-title":"High incidence of invasive group B streptococcal infections in HIV-exposed uninfected infants","volume":"126","author":"Epalza","year":"2010","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2016.12.029_b0030","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1067\/S0002-9378(03)00470-8","article-title":"The infectious origins of stillbirth","volume":"189","author":"Goldenberg","year":"2003","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.vaccine.2016.12.029_b0035","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/AOG.0b013e31817f5cb9","article-title":"Recurrence of group B streptococci colonization in subsequent pregnancy","volume":"112","author":"Turrentine","year":"2008","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.vaccine.2016.12.029_b0040","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1093\/cid\/cir325","article-title":"Incidence and severity of invasive Streptococcus pneumoniae, group A Streptococcus, and group B Streptococcus infections among pregnant and postpartum women","volume":"53","author":"Deutscher","year":"2011","journal-title":"Clin Infect Dis: Off Publ Infect Dis Soc Am"},{"key":"10.1016\/j.vaccine.2016.12.029_b0045","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJM197604012941404","article-title":"Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection","volume":"294","author":"Baker","year":"1976","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2016.12.029_b0050","doi-asserted-by":"crossref","first-page":"6793","DOI":"10.1016\/j.vaccine.2015.10.019","article-title":"Correlates of protection of serotype-specific capsular antibody and invasive group B Streptococcus disease in South African infants","volume":"33","author":"Dangor","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.12.029_b0055","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1093\/infdis\/jit549","article-title":"Maternal antibody at delivery protects neonates from early onset group B streptococcal disease","volume":"209","author":"Baker","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.12.029_b0060","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1086\/323350","article-title":"Level of maternal antibody required to protect neonates against early-onset disease caused by group B Streptococcus type Ia: a multicenter, seroepidemiology study","volume":"184","author":"Lin","year":"2001","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.12.029_b0065","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1086\/422756","article-title":"Level of maternal IgG anti-group B Streptococcus type III antibody correlated with protection of neonates against early-onset disease caused by this pathogen","volume":"190","author":"Lin","year":"2004","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.12.029_b0070","unstructured":"World Health Organization. WHO recommendations for prevention and treatment of maternal peripartum infections. Geneva, Switzerland; 2015."},{"key":"10.1016\/j.vaccine.2016.12.029_b0075","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1097\/INF.0b013e31825c4b5a","article-title":"Risk factors for neonatal sepsis and perinatal death among infants enrolled in the prevention of perinatal sepsis trial, Soweto, South Africa","volume":"31","author":"Schrag","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2016.12.029_b0080","unstructured":"World Health Organization. Pocket book of hospital care for children: guidelines for the management of common childhood illness, 2nd ed.; 2013."},{"key":"10.1016\/j.vaccine.2016.12.029_b0085","unstructured":"World Health Organization. Maternal mortality; 2015."},{"key":"10.1016\/j.vaccine.2016.12.029_b0090","unstructured":"UNICEF. Antenatal care coverage. February 2016 ed; 2016."},{"key":"10.1016\/j.vaccine.2016.12.029_b0095","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(11)61651-6","article-title":"Group B streptococcal disease in infants aged younger than 3 months: systematic review and meta-analysis","volume":"379","author":"Edmond","year":"2012","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.vaccine.2016.12.029_b0100","doi-asserted-by":"crossref","DOI":"10.1097\/INF.0000000000001233","article-title":"Disease burden of group B Streptococcus among infants in sub-Saharan Africa: a systematic literature review and meta-analysis","author":"Sinha","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2016.12.029_b0105","doi-asserted-by":"crossref","first-page":"16067","DOI":"10.1038\/nmicrobiol.2016.67","article-title":"Maternal colonization with Streptococcus agalactiae and associated stillbirth and neonatal disease in coastal Kenya","volume":"1","author":"Seale","year":"2016","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.vaccine.2016.12.029_b0110","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.jinf.2015.12.014","article-title":"Risk factors for group B Streptococcus colonisation and disease in Gambian women and their infants","volume":"72","author":"Le Doare","year":"2016","journal-title":"J Infect"},{"key":"10.1016\/j.vaccine.2016.12.029_b0115","doi-asserted-by":"crossref","DOI":"10.1097\/INF.0000000000001306","article-title":"Prevalence, serotype distribution, and mortality risk associated with group B Streptococcus colonization of newborns in rural Bangladesh","author":"Islam","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2016.12.029_b0120","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1093\/infdis\/jis605","article-title":"Capsular switching in group B Streptococcus CC17 hypervirulent clone: a future challenge for polysaccharide vaccine development","volume":"206","author":"Bellais","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.12.029_b0125","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1111\/1471-0528.13527","article-title":"Maternal group B Streptococcus-related stillbirth: a systematic review","volume":"122","author":"Nan","year":"2015","journal-title":"BJOG: An Int J Obstet Gynaecol"},{"issue":"Suppl. 4","key":"10.1016\/j.vaccine.2016.12.029_b0130","doi-asserted-by":"crossref","first-page":"D20","DOI":"10.1016\/j.vaccine.2012.11.056","article-title":"Intrapartum antibiotic prophylaxis for the prevention of perinatal group B streptococcal disease: experience in the United States and implications for a potential group B streptococcal vaccine","volume":"31","author":"Schrag","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.12.029_b0135","doi-asserted-by":"crossref","first-page":"e150","DOI":"10.1093\/cid\/ciu514","article-title":"Incidence, etiology, and outcome of bacterial meningitis in infants aged <90 days in the United Kingdom and Republic of Ireland: prospective, enhanced, national population-based surveillance","volume":"59","author":"Okike","year":"2014","journal-title":"Clin Infect Dis: Off Publ Infect Dis Soc Am"},{"key":"10.1016\/j.vaccine.2016.12.029_b0140","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S1473-3099(14)70919-3","article-title":"Incidence of invasive group B streptococcal disease and pathogen genotype distribution in newborn babies in the Netherlands over 25 years: a nationwide surveillance study","volume":"14","author":"Bekker","year":"2014","journal-title":"Lancet Infect Dis"},{"issue":"Suppl.","key":"10.1016\/j.vaccine.2016.12.029_b0145","first-page":"1","article-title":"Group B Streptococcal (GBS) disease in UK ad Irish infants younger than 90 days of age in 2014\u201315. Paper presented at the Royal College of Paediatrics and Child Health, 26\u201328 April, 2016, Liverpool, UK Abstract published","volume":"101","author":"O'Sullivan","year":"2016","journal-title":"Arch Dis Child"},{"issue":"Suppl. 4","key":"10.1016\/j.vaccine.2016.12.029_b0150","doi-asserted-by":"crossref","first-page":"D31","DOI":"10.1016\/j.vaccine.2013.05.012","article-title":"Group B streptococcal epidemiology and vaccine needs in developed countries","volume":"31","author":"Melin","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.12.029_b0155","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1097\/INF.0b013e318180b3b9","article-title":"Revisiting the need for vaccine prevention of late-onset neonatal group B streptococcal disease: a multistate, population-based analysis","volume":"27","author":"Jordan","year":"2008","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2016.12.029_b0160","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1001\/jama.299.17.2056","article-title":"Epidemiology of invasive group B streptococcal disease in the United States, 1999\u20132005","volume":"299","author":"Phares","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2016.12.029_b0165","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1053\/siny.2002.0114","article-title":"Vaccines to prevent neonatal GBS infection","volume":"7","author":"Paoletti","year":"2002","journal-title":"Semin Neonatol: SN"},{"key":"10.1016\/j.vaccine.2016.12.029_b0170","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1086\/315285","article-title":"Maternal antibody transfer in baboons and mice vaccinated with a group B streptococcal polysaccharide conjugate","volume":"181","author":"Paoletti","year":"2000","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.12.029_b0175","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/S0264-410X(98)00218-7","article-title":"Protection against experimental infection with group B Streptococcus by immunization with a bivalent protein vaccine","volume":"17","author":"Larsson","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.12.029_b0180","doi-asserted-by":"crossref","first-page":"5216","DOI":"10.1128\/IAI.65.12.5216-5221.1997","article-title":"Immunogenicity and protective efficacy of the alpha C protein of group B streptococci are inversely related to the number of repeats","volume":"65","author":"Gravekamp","year":"1997","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2016.12.029_b0185","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/infdis\/jiu067","article-title":"Group B Streptococcus beta-hemolysin\/cytolysin breaches maternal-fetal barriers to cause preterm birth and intrauterine fetal demise in vivo","volume":"210","author":"Randis","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.12.029_b0190","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1128\/IAI.26.2.599-603.1979","article-title":"Experimental vaginal colonization and mother-infant transmission of group B streptococci in rats","volume":"26","author":"Ancona","year":"1979","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2016.12.029_b0195","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S0002-9378(96)70153-9","article-title":"Ascending group B streptococcal genital infection in the rabbit model","volume":"175","author":"McDuffie","year":"1996","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.vaccine.2016.12.029_b0200","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/AOG.0000000000001190","article-title":"Maternal immunization with an investigational trivalent group b streptococcal vaccine: a randomized controlled trial","volume":"127","author":"Donders","year":"2016","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.vaccine.2016.12.029_b0205","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(16)00152-3","article-title":"Safety and immunogenicity of an investigational maternal trivalent group B Streptococcus vaccine in healthy women and their infants: a randomised phase 1b\/2 trial","author":"Madhi","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2016.12.029_b0210","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1016\/j.vaccine.2016.02.044","article-title":"A randomized, observer-blind Phase Ib study to identify formulations and vaccine schedules of a trivalent group B Streptococcus vaccine for use in non-pregnant and pregnant women","volume":"34","author":"Leroux-Roels","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.12.029_b0215","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(15)00484-3","article-title":"Group B Streptococcus vaccination in pregnant women with or without HIV in Africa: a non-randomised phase 2, open-label, multicentre trial","author":"Heyderman","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2016.12.029_b0220","doi-asserted-by":"crossref","first-page":"F403","DOI":"10.1136\/adc.2005.090472","article-title":"Association between low concentrations of antibodies to protein alpha and Rib and invasive neonatal group B streptococcal infection","volume":"91","author":"Larsson","year":"2006","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"10.1016\/j.vaccine.2016.12.029_b0225","doi-asserted-by":"crossref","first-page":"700","DOI":"10.4161\/hv.21033","article-title":"Profile: PATH's vaccine development global program","volume":"8","author":"Boslego","year":"2012","journal-title":"Hum Vaccines Immunotherapeut"},{"key":"10.1016\/j.vaccine.2016.12.029_b0230","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1016\/j.vaccine.2014.01.062","article-title":"Cost-effectiveness of a potential group B streptococcal vaccine program for pregnant women in South Africa","volume":"32","author":"Kim","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.12.029_b0235","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.vaccine.2014.12.068","article-title":"Regulatory considerations in the clinical development of vaccines indicated for use during pregnancy","volume":"33","author":"Roberts","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.12.029_b0240","first-page":"127","article-title":"The African Vaccine Regulatory Forum (AVAREF): a platform for collaboration in a public health emergency","volume":"29","author":"Akanmori","year":"2015","journal-title":"WHO Drug Inform"},{"key":"10.1016\/j.vaccine.2016.12.029_b0245","unstructured":"World Health Organization. Developing country vaccine regulators' network (DCVRN); 2012."},{"key":"10.1016\/j.vaccine.2016.12.029_b0250","unstructured":"U.S. Food and Drug Administration. Clinical development and requirement for licensure of vaccines intended for use during pregnancy to prevent disease in the infant; 2015."},{"issue":"29","key":"10.1016\/j.vaccine.2016.12.029_b0255","first-page":"341","article-title":"Global Advisory Committee on vaccine safety 15\u201316 June 2016","volume":"28","author":"World Health Organization","year":"2016","journal-title":"Wkly Epidemiol Rec"},{"issue":"Suppl. 4","key":"10.1016\/j.vaccine.2016.12.029_b0260","doi-asserted-by":"crossref","first-page":"D52","DOI":"10.1016\/j.vaccine.2013.02.029","article-title":"Considerations for a phase-III trial to evaluate a group B Streptococcus polysaccharide-protein conjugate vaccine in pregnant women for the prevention of early- and late-onset invasive disease in young-infants","volume":"31","author":"Madhi","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.12.029_b0265","doi-asserted-by":"crossref","first-page":"6396","DOI":"10.1016\/j.vaccine.2015.07.108","article-title":"Ethical considerations for designing GBS maternal vaccine efficacy trials in low-middle income countries","volume":"33","author":"White","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.12.029_b0270","series-title":"Infectious Diseases Society of America 47th annual meeting, Philadelphia, Pennsylvania","article-title":"Women receiving group B Streptococcus serotype III tetanus toxoid (GBS-III-TT) vaccine have reduced vaginal and rectal acquisition of GBS type III","author":"Baker","year":"2009"},{"key":"10.1016\/j.vaccine.2016.12.029_b0275","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.vaccine.2013.06.040","article-title":"Using the impact of pneumococcal vaccines on nasopharyngeal carriage to aid licensing and vaccine implementation; a PneumoCarr meeting report March 27\u201328, 2012, Geneva","volume":"32","author":"Goldblatt","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.12.029_b0280","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1016\/S0140-6736(16)30394-4","article-title":"Mind the gap: jumping from vaccine licensure to routine use","volume":"387","author":"O'Brien","year":"2016","journal-title":"Lancet (London, England)"},{"issue":"Suppl. 5","key":"10.1016\/j.vaccine.2016.12.029_b0285","doi-asserted-by":"crossref","first-page":"S428","DOI":"10.1093\/cid\/civ491","article-title":"Regulatory pathways that facilitated timely registration of a new group A meningococcal conjugate vaccine for Africa's meningitis belt countries","volume":"61","author":"Dellepiane","year":"2015","journal-title":"Clin Infect Dis: Off Publ Infect Dis Soc Am"},{"key":"10.1016\/j.vaccine.2016.12.029_b0290","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.vaccine.2013.11.066","article-title":"Twenty-five years of the WHO vaccines prequalification programme (1987\u20132012): lessons learned and future perspectives","volume":"33","author":"Dellepiane","year":"2015","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16312361?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16312361?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T01:22:57Z","timestamp":1601256177000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X16312361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":58,"journal-issue":{"issue":"50","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S0264410X16312361"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.12.029","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"WHO consultation on group B Streptococcus vaccine development: Report from a meeting held on 27\u201328 April 2016","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.12.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}